A Case Study - NeuBase Therapeutics, Inc.

Authors

  • Dietrich A. Stephan CEO, Chairman and Founder NeuBase Therapeutics, Pittsburgh, PA USA

DOI:

https://doi.org/10.5912/jcb995

Abstract

NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease.

Published

2021-09-02